Log in using OpenID

Blood Clotting Factors Market Will Witness a Staggering Growth During 2018-2026

Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood coagulation is a process in which blood gets converted into solid clots at time of any wound or break down of blood vessels
Blood Clotting Factors Market To Rear Excessive
Growth During 2018-2026
Blood Clotting Factors Market, by Product Type (Factors VII, Factor VIII, Factor
IX, Factor X, Factor XIII, Von Willebrand Factor, Anti-Inhibitor Coagulant
Complex, and Others), By Application (Haemophilia, Von Willebrand Disease,
Surgery, and Other Bleeding Disorders), By Technology (Plasma-derived and
Recombinant), By Distribution Channel (Hospitals Pharmacies, Retail
Pharmacies, and Online Pharmacies), By Geography - Global Industry Insights,
Trends, Outlook, and Opportunity Analysis, 2018-2026
Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood
coagulation is a process in which blood gets converted into solid clots at time of any wound or break
down of blood vessels. Clotting can prevent death from bleeding and also restrict the entry of bacteria
and viruses into the body. Haemostasis is the mechanism for blood clotting, which in controlled by a
number of factors called blood clotting factors. Deficiency of these factors can cause blood clotting
diseases such as haemophilia and von willebrand disease (VWD). According to Centre for disease
control and prevention (CDC), 2017, around 20,000 males were suffering from Haemophilia in the
U.S. Click To Read More On Blood Clotting Factors Market.
Approval of novel drugs in key markets such as North America and Europe is expected to boost
the growth in blood clotting factors market
In November 2017, the U.S. FDA approved Hemlibra (Emicizumab-kxwh) developed by Roche AG,
for the treatment of Haemophilia A patient with inhibitors. This was the first approval by FDA in about
20 years to treat people with hemophilia A with inhibitors. Moreover, FDA approved Shire Plc’s
Adynovate for treatment of hemophilia A patients. The drug has also been approved for use in surgical
setting for both category of patients, adult and pediatric. In January 2018, the drug (Adynovate) was
granted marketing authorization in European Union (EU). In EU, the drug got approval for adults and
adolescents suffering from Hemophilia A. These approvals will provide the alternate option for patients
suffering from hemophilia. Introduction of these drugs in market is expected to propel growth of the
blood clotting factors market over the forecast period.
Low adherence to treatment among patients with Hemophilia has hindered the growth in this market.
According to The National Haemophilia Foundation, about 75% of people suffering from hemophilia
either don’t receive or don’t have access to complete treatment.
Ask For Sample Copy Of This Business Research Report :
North America is expected to hold a dominant position in blood clotting factors market, owing to
increased awareness about the disease and availability of wide range of treatment options
Haemophilia is a rare disorder affecting very small fraction of population across the globe.
Pharmaceutical companies invest less amount on development of such drugs due to low return on
investment. However, FDA has recognized this fact and has formulated favorable policy to motivate
companies to invest in this area. Orphan Drug Act that applies to company operating in this area
provides three special incentives i.e. 7 years exclusivity period, tax credit and waiver of prescription
drug user fees. Due to such policy, the company has invested in rare disease research which has led to
development of products such as Hemlibra (Emicizumab-kxwh), Adynovate and Others. Owing to
above mentioned factors, North America has dominated the market and it is also expected to retain
position over the forecast period. Asia Pacific is expected to witness robust growth in the market due to
improved ratio of patients suffering from disease and patients receiving treatment. Availability of
generic products, at much lower price compared to branded product, in the market is expected to fuel
growth of the market in Asia Pacific.
Key players operating in Blood clotting factors market include Shire Plc, Baxter International Inc.,
Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG,
Biogen Idec, and Kedrion S.P.A.
Segmentation of Blood Clotting Factors Market
By Product Type –
•Factor VII
•Factor VIII
•Factor IX
•Factor X
•Factor XIII
•Von Willebrand Factor
•Anti-Inhibitor Coagulant Complex
By Application •Haemophilia
•Haemophilia A
•Haemophilia B
•Von willebrand disease (VWD)
•Other bleeding disorders
By Technology
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called
PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps
biotechnology and pharmaceutical companies to analyze the market trend, competition, and market
potential. For more information or to access this database, kindly click on the below link or contact at
[email protected]
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran303   documents Email
Health and Medicine
File Size
384 KB
Report inappropriate content